The pharmaceutical company, Lupin has informed that it has signed a licensing pact with Alvion Pharmaceuticals. Under this deal, they will commercialize medicines for cardiometabolic diseases in the Southeast Asia region. Lupin said that it will stay committed to providing affordable treatment options to healthcare providers and patients. After the successful deal, Lupin’s Regional Head of Southeast Asia, Gabriel Georgy said: ''Forming a long-term collaboration with Alvion to launch a range of therapies will allow Lupin to expand its footprint across Southeast Asia with quality cost-effective alternatives for patients and the healthcare system.” Lupin further said that by commercializing cardiometabolic drugs in Southeast Asia, it will contribute significantly to improve the quality of healthcare and access to medicines. Gabriel Georgy also told that both companies have rich experience in developing and launching products and this agreement will further establish Lupin as a strong pharmaceutical company in the region. While expressing his views on the newly inked deal, CEO of Alvion Pharmaceuticals, John Buoros said: ''Being a leader in value-added medicines, Alvion shall support Lupin's activities aiming to position both companies at the forefront for both molecules.”